Miquel Duran-Frigola

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7136476/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	A reference map of the human binary protein interactome. Nature, 2020, 580, 402-408.	27.8	724
2	Widespread Expansion of Protein Interaction Capabilities by Alternative Splicing. Cell, 2016, 164, 805-817.	28.9	479
3	Systems analysis of intracellular pH vulnerabilities for cancer therapy. Nature Communications, 2018, 9, 2997.	12.8	277
4	Extending the small-molecule similarity principle to all levels of biology with the Chemical Checker. Nature Biotechnology, 2020, 38, 1087-1096.	17.5	78
5	Residues Coevolution Guides the Systematic Identification of Alternative Functional Conformations in Proteins. Structure, 2016, 24, 116-126.	3.3	56
6	Isolation of Human Colon Stem Cells Using Surface Expression of PTK7. Stem Cell Reports, 2015, 5, 979-987.	4.8	52
7	Analysis of Chemical and Biological Features Yields Mechanistic Insights into Drug Side Effects. Chemistry and Biology, 2013, 20, 594-603.	6.0	50
8	Bioactivity descriptors for uncharacterized chemical compounds. Nature Communications, 2021, 12, 3932.	12.8	44
9	Structural Systems Pharmacology: The Role of 3D Structures in Next-Generation Drug Development. Chemistry and Biology, 2013, 20, 674-684.	6.0	42
10	Recycling side-effects into clinical markers for drug repositioning. Genome Medicine, 2012, 4, 3.	8.2	39
11	Drug sensitivity in cancer cell lines is not tissue-specific. Molecular Cancer, 2015, 14, 40.	19.2	39
12	Detecting similar binding pockets to enable systems polypharmacology. PLoS Computational Biology, 2017, 13, e1005522.	3.2	35
13	Antigen-stimulated PBMC transcriptional protective signatures for malaria immunization. Science Translational Medicine, 2020, 12, .	12.4	33
14	A community challenge for a pancancer drug mechanism of action inference from perturbational profile data. Cell Reports Medicine, 2022, 3, 100492.	6.5	33
15	IntSide: a web server for the chemical and biological examination of drug side effects. Bioinformatics, 2015, 31, 612-613.	4.1	28
16	Dual fluorescence in 9-amino-2,7,12,17-tetraphenylporphycene. Physical Chemistry Chemical Physics, 2011, 13, 10326.	2.8	26
17	Systematic Identification of Molecular Links between Core and Candidate Genes in Breast Cancer. Journal of Molecular Biology, 2015, 427, 1436-1450.	4.2	24
18	Connecting chemistry and biology through molecular descriptors. Current Opinion in Chemical Biology, 2022, 66, 102090.	6.1	24

MIQUEL DURAN-FRIGOLA

#	Article	IF	CITATIONS
19	A chemo-centric view of human health and disease. Nature Communications, 2014, 5, 5676.	12.8	23
20	Systems-Wide Prediction of Enzyme Promiscuity Reveals a New Underground Alternative Route for Pyridoxal 5'-Phosphate Production in E. coli. PLoS Computational Biology, 2016, 12, e1004705.	3.2	20
21	Formatting biological big data for modern machine learning in drug discovery. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1408.	14.6	17
22	Modifications of Microvascular EC Surface Modulate Phototoxicity of a Porphycene anti-ICAM-1 Immunoconjugate; Therapeutic Implications. Langmuir, 2013, 29, 9734-9743.	3.5	15
23	Cervical cancer screening outcomes in Zambia, 2010–19: a cohort study. The Lancet Global Health, 2021, 9, e832-e840.	6.3	15
24	Encircling the regions of the pharmacogenomic landscape that determine drug response. Genome Medicine, 2019, 11, 17.	8.2	14
25	Drug repositioning beyond the low-hanging fruits. Current Opinion in Systems Biology, 2017, 3, 95-102.	2.6	11
26	Patientâ€reported reasons for declining sameâ€day antiretroviral therapy initiation in routine HIV care settings in Lusaka, Zambia: results from a mixedâ€effects regression analysis. Journal of the International AIDS Society, 2020, 23, e25560.	3.0	11
27	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	8.2	10
28	Rationalizing Drug Response in Cancer Cell Lines. Journal of Molecular Biology, 2018, 430, 3016-3027.	4.2	9
29	Exploring the OncoGenomic Landscape of cancer. Genome Medicine, 2018, 10, 61.	8.2	7
30	Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models. Genome Medicine, 2021, 13, 168.	8.2	7
31	Charting the molecular links between driver and susceptibility genes in colorectal cancer. Biochemical and Biophysical Research Communications, 2014, 445, 734-738.	2.1	6
32	A PanorOmic view of personal cancer genomes. Nucleic Acids Research, 2017, 45, W195-W200.	14.5	6
33	Bioactivity Profile Similarities to Expand the Repertoire of COVID-19 Drugs. Journal of Chemical Information and Modeling, 2020, 60, 5730-5734.	5.4	3
34	Computational Applications in Secondary Metabolite Discovery (CAiSMD): an online workshop. Journal of Cheminformatics, 2021, 13, 64.	6.1	3
35	Evaluation of kidney function among people living with HIV initiating antiretroviral therapy in Zambia. PLOS Global Public Health, 2022, 2, e0000124.	1.6	1
36	Cover Image, Volume 9, Issue 6. Wiley Interdisciplinary Reviews: Computational Molecular Science, 2019, 9, e1451.	14.6	0

#	Article	IF	CITATIONS
37	A Community Challenge for Pancancer Drug Mechanism of Action Inference from Perturbational Profile Data. SSRN Electronic Journal, 0, , .	0.4	0
38	Extending the Small Molecule Similarity Principle to All Levels of Biology. SSRN Electronic Journal, 0,	0.4	0